<?xml version="1.0" encoding="UTF-8"?>
<p>Along with the evaluation of convalescent plasma from blood donors, the plasma industry could take future steps, manufacturing concentrated hyperimmune globulin preparations that contain standardized antibody doses and could provide a further reach in terms of health setting administering therapy.
 <sup>
  <xref rid="R34" ref-type="bibr">34</xref>
 </sup> As a whole, the promising results of convalescent plasma transfusion could change the course of COVID-19. The formulation, namely convalescent plasma or hyperimmune globulin, as well as the optimal time frame, remain to be identified in the future.
</p>
